EyePoint Pharmaceuticals (NASDAQ:EYPT) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

EyePoint Pharmaceuticals (NASDAQ:EYPT) announced its quarterly earnings data on Wednesday. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10), Zacks reports. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%.

EyePoint Pharmaceuticals Stock Down 0.7 %

EYPT traded down $0.04 during trading on Wednesday, hitting $6.04. The company’s stock had a trading volume of 53,475 shares, compared to its average volume of 832,838. The business’s 50 day simple moving average is $7.31 and its 200-day simple moving average is $8.50. The firm has a market cap of $412.24 million, a PE ratio of -3.08 and a beta of 1.51. EyePoint Pharmaceuticals has a one year low of $5.54 and a one year high of $26.76.

Wall Street Analysts Forecast Growth

EYPT has been the topic of a number of research analyst reports. Robert W. Baird lowered their price target on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. Citigroup began coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $33.00 price objective for the company. Finally, Chardan Capital restated a “buy” rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.